Sandoz

We are committed to mitigating the impact of AMR and ensuring we are prioritizing responsible manufacturing. Achieving the BSI Kitemark™ for Minimized Risk of AMR is a key step to keep modern healthcare working. #WAAW #AMR #ResponsibleManufacturing #ResponsibleAccess #ResponsibleUse #ESG #GoingBlueForAMR

At Sandoz, we are committed to driving LGBTQI+ inclusion, by supporting the United Nations Standards of Conduct for Business. Today, on the International Transgender Day of Remembrance, along with our Executive Sponsor Keren Haruvi Snir, we take a moment to acknowledge the lives of transgender and gender-diverse individuals who lost their lives due to acts of violence and hate. This community continues to face high levels of discrimination, misunderstanding, and violence simply for being themselves. We continue to work to create an inclusive environment where everyone can feel seen, heard, and safe. Learn more at https://lnkd.in/dbxSxAKP #SandozLife #TDoR2024 #TransRightsAreHumanRights

Join us on Nov 21st as our Global Head of Antimicrobial Resistance Dr. Boumediene Soufi takes part in a panel discussion hosted by the Access to Medicine Foundation on how pharma can contribute to the fight against #AMR.    Register for the Webinar via the link below👇   #GoingBlueForAMR #ESG

This World Antimicrobial Resistance Awareness Week, we’re spotlighting a critical issue: safeguarding the effectiveness of antibiotics, the backbone of modern medicine, against the rising threat of AMR. Successfully combating AMR requires a wide-ranging public-private collaboration effort. That’s why, as the leading global provider of general antibiotics, we’re proud to work in partnership with the AMR Industry Alliance, European Commission One Health expert network and the World Health Organization Access to Novel Antimicrobials group to champion responsible manufacturing, access, and use of antimicrobial medicines.   Join us in taking action this #WAAW to make a difference and keep modern healthcare working.   #AMR #ResponsibleManufacturing #ResponsibleAccess #ResponsibleUse #ESG #GoingBlueForAMR

How to keep Europe on the map - what is needed to strengthen EU biosimilar manufacturing to meet the growing demand for medicines?   That is the question we asked public health and policy experts during last week’s panel discussion on the importance of establishing a strong European biomanufacturing footprint.   What followed was an animated discussion about the need for a robust biomanufacturing ecosystem to ensure a sustainable future for biosimilar medicines in the European Union. The panelists highlighted how strengthening European production capabilities through continued investments is key to ensuring supply chain resilience, and driving economic growth through high-tech jobs and innovation.    We’d like to thank Matevž Frangež and the Slovenian Ministrstvo za gospodarstvo, turizem in šport / Ministry of the Economy, Tourism and Sport for their partnership in co-hosting this important conversation.    Many thanks also to our expert panel – Antonella Cardone, Anne Marie D., Giulia Del Brenna and Vytenis Andriukaitis – as well as our moderator Adrian van den Hoven for their invaluable contributions.   Keeping Europe on the map and advancing access to biosimilars for patients everywhere will require strategic investments, talent development, and long-term planning. Collaboration will be key.  We are proud to already be doing our part in building the foundations for a more sustainable and brighter future for biosimilar manufacturing together with Lek Pharmaceuticals.    Read more about what our Chief Manufacturing and Supply Officer, Glenn A. Gerecke, PhD says about the need to evolve biomanufacturing and create more sustainable policies to strengthen biosimilar manufacturing globally here:  https://lnkd.in/e8eDX-P3

As #GlobalBiosimilarsWeek draws to a close, we want to thank the IGBA - International Generic and Biosimilar medicines Association and everyone who participated for their dedication in creating a movement around advancing access to biosimilars!     Biosimilars are instrumental in ensuring and expanding patient access to biologic medicines and are indispensable to the long-term sustainability of healthcare systems. They create competition, support supply of essential medicines and fuel innovation while offering more affordable treatment options.    A united, multistakeholder approach as taken by Act4Biosimilars is key to overcoming the various policy, regulatory, and health system barriers that stand in the way of biosimilar Approvability, Acceptability, Accessibility and Affordability.     We must continue to collaborate to create a strong and sustainable global environment for biosimilars. This is key to stimulating biosimilar development, pioneering access for patients and ultimately helping more people across the world live healthier and happier lives. 

We simply cannot take biosimilar medicines for granted. To maximize their potential and unlock their benefits for patients and healthcare systems across the globe, we must create the right market conditions that will allow them to thrive.   This #GlobalBiosimilarsWeek, we’re proud to support Digestive Cancers Europe in raising awareness of the policy shifts needed to advance patient access to #biosimilar medicines.     Want to learn more about the vital role of biosimilars in treating digestive cancers?    Check out DiCE’s Biosimilars Education page:   https://lnkd.in/dXq3cJ4C   

The current intellectual property and patent regulatory landscape has allowed some reference biologics to hold market monopolies for longer than justified.    The theme for this year’s #GlobalBiosimilarsWeek, ‘Advancing Access to Biosimilars,’ is a great reminder that we must keep working hard together to ensure that legal frameworks are balanced and built with patients in mind.    This is one of the key barriers we need to overcome to promote healthy biosimilar competition and ensure we are pioneering access for patients. 

To date, biosimilars are developed based on the totality of evidence, using extensive advanced analytical studies, as well as clinical Phase I and III studies.     However, extensive advances in science and a review of the scientific contributions of Phase III clinical studies have made it clear that we need to streamline #biosimilar development.      As part of this year’s #GlobalBiosimilarsWeek, the IGBA - International Generic and Biosimilar medicines Association is hosting a webinar on “Streamlining the Regulatory Process to Advance Access to Biosimilars” on November 13th, 3 pm CET.      For more information or to register, visit:  https://lnkd.in/d_cpUnQ  

The Sandoz Device Development Centre (SDDC) in Cambridge, UK has been inaugurated – a purpose-built, state-of-the-art facility that will further enrich our capabilities to advance medical device combination products and successfully deliver on our pipeline. At the official ribbon-cutting ceremony, Richard Saynor, CEO, Claire D'Abreu-Hayling, CSO and Diane DiGangi Trench, Country Head and General Manager for Sandoz UK & Ireland, were joined by national leaders championing life sciences research and healthcare in the UK including Baroness Gillian Merron, Parliamentary Under-Secretary of State for Patient Safety, Women's Health and Mental Health and William Mullins, Deputy Director, Office for Life Sciences. The opening of the SDDC calls for the recruitment of talented scientists, engineers, and project managers who are eager to join us in our Purpose of #PioneeringAccess for patients. Read more: https://lnkd.in/dRVt8T-a #Biosimilars #ComplexGenerics